Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
Human papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10–12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2184605 |
| _version_ | 1797673096222605312 |
|---|---|
| author | Tak Hong Cheung Sally Shuk Yee Cheng Danny Hsu Queenie Wing-Lei Wong Andrew Pavelyev Isaya Sukarom Kunal Saxena |
| author_facet | Tak Hong Cheung Sally Shuk Yee Cheng Danny Hsu Queenie Wing-Lei Wong Andrew Pavelyev Isaya Sukarom Kunal Saxena |
| author_sort | Tak Hong Cheung |
| collection | DOAJ |
| description | Human papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10–12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys were not included. The current study estimated the potential health and economic impact of a routine gender-neutral vaccination (GNV) approach compared with the current female-only vaccination (FOV) strategy. We used a dynamic transmission model, adapted to Hong Kong. The model estimates changes in HPV-related disease incidence and mortality, treatment costs (in 2019 Hong Kong dollars), quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs) over a 100-year time horizon. The base case analysis compared FOV with the 9vHPV vaccine with routine GNV (coverage rate 70%) for the prevention of HPV-related diseases. Compared with a FOV approach, routine GNV with the 9vHPV vaccine is predicted to provide greater reductions in cumulative HPV-related disease incidence and mortality, as well as lower HPV-related treatment costs. In the base case analysis, the ICER was $248,354 per QALY for routine GNV. As compared with FOV, routine GNV fell below the cost-effectiveness ceiling of $382,046/year for Hong Kong. These results highlight the potential value of a routine GNV program with the 9vHPV vaccine among 12-year-olds in Hong Kong to reduce the public health and economic burden of HPV-related diseases. |
| first_indexed | 2024-03-11T21:39:38Z |
| format | Article |
| id | doaj.art-496f8e84a13843888584611f7f3f803e |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:38Z |
| publishDate | 2023-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-496f8e84a13843888584611f7f3f803e2023-09-26T13:25:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-08-0119210.1080/21645515.2023.21846052184605Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong KongTak Hong Cheung0Sally Shuk Yee Cheng1Danny Hsu2Queenie Wing-Lei Wong3Andrew Pavelyev4Isaya Sukarom5Kunal Saxena6The Chinese University of Hong KongMSD Hong KongMSD Hong KongMSD Hong KongMerck & Co., IncMSD ThailandMerck & Co., IncHuman papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10–12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys were not included. The current study estimated the potential health and economic impact of a routine gender-neutral vaccination (GNV) approach compared with the current female-only vaccination (FOV) strategy. We used a dynamic transmission model, adapted to Hong Kong. The model estimates changes in HPV-related disease incidence and mortality, treatment costs (in 2019 Hong Kong dollars), quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs) over a 100-year time horizon. The base case analysis compared FOV with the 9vHPV vaccine with routine GNV (coverage rate 70%) for the prevention of HPV-related diseases. Compared with a FOV approach, routine GNV with the 9vHPV vaccine is predicted to provide greater reductions in cumulative HPV-related disease incidence and mortality, as well as lower HPV-related treatment costs. In the base case analysis, the ICER was $248,354 per QALY for routine GNV. As compared with FOV, routine GNV fell below the cost-effectiveness ceiling of $382,046/year for Hong Kong. These results highlight the potential value of a routine GNV program with the 9vHPV vaccine among 12-year-olds in Hong Kong to reduce the public health and economic burden of HPV-related diseases.http://dx.doi.org/10.1080/21645515.2023.2184605human papillomavirusvaccinehead and neck cancercost-effectivenesshong kong |
| spellingShingle | Tak Hong Cheung Sally Shuk Yee Cheng Danny Hsu Queenie Wing-Lei Wong Andrew Pavelyev Isaya Sukarom Kunal Saxena Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong Human Vaccines & Immunotherapeutics human papillomavirus vaccine head and neck cancer cost-effectiveness hong kong |
| title | Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong |
| title_full | Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong |
| title_fullStr | Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong |
| title_full_unstemmed | Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong |
| title_short | Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong |
| title_sort | health impact and cost effectiveness of implementing gender neutral vaccination with the 9 valent hpv vaccine in hong kong |
| topic | human papillomavirus vaccine head and neck cancer cost-effectiveness hong kong |
| url | http://dx.doi.org/10.1080/21645515.2023.2184605 |
| work_keys_str_mv | AT takhongcheung healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong AT sallyshukyeecheng healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong AT dannyhsu healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong AT queeniewingleiwong healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong AT andrewpavelyev healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong AT isayasukarom healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong AT kunalsaxena healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong |